Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 9/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | TLR2 | O60603 | 3/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | CFTR | P13569 | 1/20 | 0.54 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450860 | 0.90 | MEN1 (0.78) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL5448370 | 0.88 | MEN1 (0.68) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL8290385 | 0.87 | MEN1 (0.74) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL5458514 | 0.87 | FLT3 (0.61) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL5455906 | 0.87 | FLT3 (0.74) | KMT2AMEN1ALDH1A1MAPTFLT3 | |
| SCHEMBL5451378 | 0.86 | TNIK (0.52) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL5457809 | 0.85 | MEN1 (0.55) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL4234573 | 0.84 | FLT3 (0.72) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL5455812 | 0.84 | MAPT (0.58) | KMT2AMEN1ALDH1A1GAAMAPT | |
| SCHEMBL8290923 | 0.83 | RAB9A (0.80) | KMT2AMEN1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | KMT2A 4785/4885MEN1 2891/4885ALDH1A1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.